Can someone please explain the difference between SubB2M-(CA15.3 & CA125) and SubB2M SPR?
It appears the SubB2M-based SPR test for detection of Neu5Gc for cancer risk assessment and SubB2M-(CA15.3 & CA125) are for cancer
monitoring. What is the difference between risk assessment and monitoring?
Also, it looks like those results that caused the SP to skyrocket 2 years ago were SPR results, and the CA125 results were good but not as great (see slide 18). I can gather from slide 11, that the 2023 market launch that we're all waiting for is for CA15.3 & CA125 and not SubB2M SPR - why are management not prioritising the SPR tests to commercialisation?
Ann: Healthcare Conference Investor Presentation, page-3
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.005(0.90%) |
Mkt cap ! $62.03M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 57.0¢ | 55.5¢ | $19.68K | 35.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3264 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 870 | 1 |
View Market Depth
| Last trade - 14.25pm 03/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |